Arno Therapeutics, Inc.
ARNI
$0.0001
$0.000.00%
OTC PK
| 09/30/2016 | 06/30/2016 | 03/31/2016 | 12/31/2015 | 09/30/2015 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.11% | -5.77% | -7.69% | 3.58% | -43.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -22.38% | -16.80% | -26.85% | -22.78% | -49.35% |
| Operating Income | 22.38% | 16.80% | 26.85% | 22.78% | 49.35% |
| Income Before Tax | -466.61% | 37.81% | -9.45% | -187.55% | -526.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -466.61% | 37.81% | -9.45% | -187.55% | -526.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -466.61% | 37.81% | -9.45% | -187.55% | -526.16% |
| EBIT | 22.38% | 16.80% | 26.85% | 22.78% | 49.35% |
| EBITDA | 22.40% | 16.81% | 26.86% | 22.76% | 49.35% |
| EPS Basic | -158.56% | 69.49% | 42.35% | -187.52% | -526.92% |
| Normalized Basic EPS | -158.65% | 69.48% | 42.39% | -180.46% | -524.49% |
| EPS Diluted | -158.56% | 69.49% | 42.35% | -208.72% | -526.92% |
| Normalized Diluted EPS | -158.65% | 69.48% | 42.39% | -197.84% | -620.00% |
| Average Basic Shares Outstanding | 119.05% | 103.65% | 89.98% | 0.00% | 0.16% |
| Average Diluted Shares Outstanding | 119.05% | 103.65% | 89.98% | -17.75% | -17.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |